---
title: "Choosing Between NAD Precursors | HealthRX.com"
description: "NMN and NR both raise blood NAD+ in human trials, but neither has an established clinical benefit, and no trial compared them. See the doses and evidence."
url: https://healthrx.com/classes-nad-precursors/when-to-pick-which
publisher: HealthRX.com
---


HealthRX.com

NMN and NR both raise blood NAD+, but neither is proven to help

[Print or save as PDF](https://healthrx.com/printables/classes-nad-precursors/when-to-pick-which?print=1)

Key numbers

- 250 mg/day NMN dose in a 12-week placebo-controlled trial of 30 healthy adults; NAD+ rose significantly Source: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35479740/), as cited Oct 30, 2026
- 1,250 mg Highest NMN dose tested for safety, given for up to 4 weeks to 31 healthy adults with no severe adverse events Source: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36002548/), as cited Oct 30, 2026
- 2,000 mg/day Total daily NR dose in a 12-week placebo trial of 40 obese men; no gain in insulin sensitivity Source: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29992272/), as cited Oct 30, 2026
- 3,000 mg/day Highest NR dose tested, taken for 4 weeks by people with Parkinson's disease; no moderate or severe adverse events Source: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/38016950/), as cited Oct 30, 2026

HealthRX.com quick answer. NMN and NR both raise blood NAD+ in human trials, but neither has an established clinical benefit, and the trials tested each against placebo, so they cannot show which is better [1][2][3][4]. Nicotinic acid's evidence is for lipid lowering at gram doses, a different goal [5]. Neither NMN nor NR is an FDA-approved drug [6].

At a glance

- What the class is / Vitamin B3-related precursors the body converts to NAD+, a coenzyme and a substrate for sirtuins and PARP enzymes [10]
- Agents with randomized NAD+ trials / NMN and NR [1][2]
- Blood NAD+ / Rises with oral NMN in several randomized trials and with oral NR in a crossover trial [1][2]
- Muscle NAD+ / Did not rise with NR 1 g/day in 12 men aged 70-80 [8]
- Functional benefit / Not established; two NMN trials reported performance signals, but 2025 meta-analyses found no effect on strength, gait speed or most metabolic labs [7][9][3][4]
- Doses tested / NMN 250 to 1,250 mg/day; NR 1,000 to 3,000 mg/day in repeated-dose trials (studied doses, not recommendations) [11][12]
- Regulatory status / Neither NMN nor NR is FDA-approved for any use; NMN is treated as lawful in supplements after FDA's 2025 reversal [6]
- Injectable NAD+ / A compounded product, not an FDA-approved drug [13]

## Are the four NAD+ precursors interchangeable?

They are grouped as one class because all of them feed NAD+ synthesis. NAD+ itself is a coenzyme in cellular energy metabolism and the substrate for sirtuins and PARP enzymes [10]. The human data behind them are not equivalent, though. NMN and NR have randomized trials that measured blood NAD+ before and after dosing [1][2]. Nicotinic acid's outcome evidence comes from its use as a lipid drug at gram doses [5].

What people on Reddit report

Readers comparing plain niacinamide with nicotinamide riboside for the same goal, and what they noticed after switching or while deciding.

Pitiful_Editor_113 · NicotinamideRiboside

I've read in various places not to take the nicotinamide Riboside, but then I've also read ppl are taking the riboside.

Asks whether to take niacinamide or NR, having read conflicting advice about NR.

[Read the source discussion](https://www.reddit.com/r/NicotinamideRiboside/comments/1ngq674/which_nicotinamide_riboside_or_niacinamide/)

Resident_Ant_6691 · NicotinamideRiboside

The NR dose is higher and my energy's been noticeably better, which wasn't happening with plain niacinamide.

Switched from plain niacinamide to an NR product and reports more energy than with niacinamide alone.

[Read the source discussion](https://www.reddit.com/r/NicotinamideRiboside/comments/1ngq674/which_nicotinamide_riboside_or_niacinamide/)

## NMN: what the human trials measured

Several randomized trials tested NMN at 250 mg/day. In one, 30 healthy adults took 250 mg/day or placebo for 12 weeks (15 per group); whole-blood NAD+ increased significantly and no adverse effects or laboratory abnormalities appeared [1]. In older men given 250 mg/day for 6 or 12 weeks, blood NAD+ and its metabolites rose, with nominally significant improvements in gait speed and left grip that the authors said needed confirmation in larger studies; body composition did not change [15]. A 12-week trial of 108 older Japanese adults assessed sleep, fatigue and physical performance; every group, including placebo, improved on the five-times sit-to-stand test, with the largest effect sizes in the group taking NMN in the afternoon (d=0.72 for sit-to-stand, d=0.64 for drowsiness) [9].

The dose-ranging trial gives the clearest picture of daily dosing. Eighty healthy middle-aged adults took placebo or NMN 300, 600 or 900 mg/day for 60 days. Blood NAD rose in every NMN group compared with placebo and baseline (all p ≤ 0.001) and was highest at 600 and 900 mg. Six-minute walk distance was greater than placebo in all NMN groups, and no safety issues were reported [7]. Raising blood NAD at 600 or 900 mg a day of NMN is the benchmark people hold up when weighing [NAD+ injections](https://healthrx.com/products/nad-injection), though that trial tested the oral route.

The highest daily dose tested for safety was 1,250 mg once daily for up to 4 weeks in 31 healthy adults aged 20-65, randomized and placebo-controlled: no severe adverse events and no changes beyond normal physiological variation in hematology, biochemistry, urine or body composition [11].

Physical-function results have been mixed. A 2025 systematic review and meta-analysis of randomized trials in older adults (mean age 60.9 to 83 years) found NMN had no significant effect on skeletal muscle index, handgrip strength, gait speed or five-times chair stand [3]. A second 2025 meta-analysis, 12 studies and 513 participants, found NMN raised blood NAD but most clinical outcomes, including fasting glucose, triglycerides and cholesterol, were not significantly different from control; risk of bias had some concerns in 7 studies and was high in 5 [4].

## NR: what the human trials measured

In a randomized, placebo-controlled crossover trial in healthy middle-aged and older adults, NR was well tolerated and stimulated NAD+ metabolism [2]. Blood pressure changes were not significant; a post hoc subgroup with elevated baseline blood pressure showed a larger systolic difference, which the authors described as exploratory [2]. Mild events such as nausea, flushing, leg cramps and bruising occurred, with no serious events [2].

In a separate 21-day crossover trial, 12 men aged 70-80 took NR 1 g/day. Muscle NAD+ did not rise (210 vs 197 pmol/mg, p=0.22), while NAAD, a marker of NAD+ synthesis, doubled; mitochondrial respiration, [grip strength](https://healthrx.com/labs-grip-strength/what-it-measures), insulin sensitivity and muscle blood flow were unchanged, and circulating IL-6 and IL-5 were lower than at baseline [8].

A larger metabolic trial was also null: 40 sedentary obese men aged 40-70 took NR 1,000 mg twice daily (2,000 mg/day) or placebo for 12 weeks, with no improvement in insulin sensitivity by clamp, energy expenditure, lipolysis or body composition, and no serious adverse events [16].

Higher doses have been tested in Parkinson's disease. In a 20-person trial (10 on NR), NR 1,500 mg twice daily (3,000 mg/day) for 4 weeks produced no moderate or severe adverse events, raised blood NAD+ up to 5-fold, and caused a slight initial rise in serum [homocysteine](https://healthrx.com/labs-homocysteine/what-it-measures) [12]. In a separate phase I trial, 30 newly diagnosed untreated patients took NR 1,000 mg/day or placebo for 30 days; it was well tolerated, brain NAD rose but variably, and the clinical improvement signal was mild [17]. In the high-dose trial, the apparent improvement in MDS-UPDRS scores was associated with a shorter interval since the last levodopa dose, so that result is confounded [12].

## Which precursor has data on insulin sensitivity?

The most-cited NMN metabolic trial enrolled postmenopausal women with [prediabetes](https://healthrx.com/conditions-prediabetes/diagnosis-algorithm) who were overweight or obese, randomized, placebo-controlled and double-blind over 10 weeks. Insulin-stimulated glucose disposal measured by clamp rose after NMN and did not change after placebo, and muscle insulin signalling (AKT and mTOR phosphorylation) increased [10]. The paper drew a published comment and response disputing its analysis [10]. On the NR side, 2,000 mg/day for 12 weeks did not improve insulin sensitivity in obese men [16].

## What about niacin and nicotinamide?

Nicotinic acid has a long history as a lipid drug: at gram doses it lowers VLDL, LDL and Lp(a) and raises HDL more than any other drug, according to a 2005 review [5]. That evidence concerns lipids at gram doses, not NAD+ repletion. Nicotinamide is the amide form of niacin; in laboratory studies it inhibits Sir2 enzymes noncompetitively [14]. That is a laboratory observation, not a human dose-response finding.

## What is the regulatory status of each product?

Neither NMN nor NR is an FDA-approved drug, and no NAD+ precursor is approved to treat aging or any disease [6]. FDA now treats NMN as eligible for sale as a dietary supplement, subject to new-dietary-ingredient requirements [6]. That follows a reversal: trade press reported that in 2022 FDA told two ingredient makers that NMN could not be marketed as a dietary supplement under the drug-exclusion clause, a citizen petition followed in March 2023 [18], and on 2025-09-29 FDA posted a response concluding that NMN is not excluded from the supplement definition [6]. NMN is not banned.

For NR, FDA answered a GRAS notice from ChromaDex (GRN 000635) with a 'no questions at this time' letter dated 2016-08-03 and stated that it had not made its own GRAS determination [19].

Injectable or IV NAD+ is a compounded product rather than an FDA-approved drug [13].

## Tolerability and what is not known

The trial record for NMN and NR is short and small. Long-term safety data beyond about 12 weeks are lacking, and the trials enrolled 12 to 140 people [20]. Pregnancy, breastfeeding, children, and people with cancer or kidney or liver disease were not studied, so safety in those groups is unknown [20]. Chronic NAD+ boosting has been raised as a theoretical cancer concern, but no human data were identified [20]. At the doses tested, NMN from 250 to 1,250 mg/day produced no safety issues in the trials above [1][7][11], and NR at 1,000 to 3,000 mg/day produced mild events such as nausea, flushing, leg cramps and bruising but no serious ones [2][12][16].

Questions worth asking

Choose the questions you want to keep Which NAD+ precursor has the most human trial data for my goal? Do the trials show that NMN or NR is better than the other? What dose of NMN or NR was studied, and is that the dose I would take? Is nicotinamide riboside a different product from niacinamide, and what does each one do? How long have the safety studies of NMN or NR lasted? Could a NAD+ precursor interact with my current prescription medicines?

## Can a NAD+ precursor be taken with prescription drugs?

A 2023 review identified no human drug-interaction studies of NMN or NR covering CYP enzymes, drug transporters or pharmacodynamic interactions [20]. Neither safety with, nor an interaction with, a specific prescription drug has been established. In the high-dose NR trial in Parkinson's disease, the apparent clinical improvement tracked with a shorter interval since the last levodopa dose, which confounds that result [12].

Printable question sheet

NMN, NR and NAD+ precursor questions for your prescriber

Use this sheet before a visit or pharmacy talk about choosing between NMN, NR, nicotinic acid or injectable NAD+. Fill it in by hand, bring it along, and keep it at home to track what you tried.

[Open the fill-in sheet](https://healthrx.com/printables/classes-nad-precursors/when-to-pick-which) Fill it in, print it or save it as a PDF. No sign-up.

Frequently asked questions

Which NAD+ precursor raises NAD+ the most?

The cited trials tested each precursor against placebo, so they cannot show which raises blood NAD+ more. Randomized trials show NMN raises blood NAD+ [1][7], and a crossover trial found NR stimulated NAD+ metabolism [2]. NMN has a 60-day trial of 300, 600 and 900 mg/day, with the highest blood NAD at 600 and 900 mg [7]; NR has a single-dose study showing dose-dependent changes in the blood NAD+ metabolome at 100, 300 and 1,000 mg [21].

Does NR raise NAD+ inside muscle?

Not in the one trial that measured it. In a 21-day crossover trial, 12 men aged 70-80 took NR 1 g/day; muscle NAD+ did not rise (210 vs 197 pmol/mg, p=0.22), although NAAD, a marker of NAD+ synthesis, doubled, and mitochondrial respiration was unchanged [8].

Is NMN lawful to sell as a dietary supplement in the US?

Yes, as FDA currently treats it. In its response posted 29 September 2025, FDA concluded NMN is not excluded from the supplement definition because it found evidence NMN was sold as a supplement before it was authorized for drug investigation [6]. It remains a new dietary ingredient, so makers must file an NDI notification [6].

Do NAD+ precursors interact with prescription drugs?

A 2023 review identified no human interaction studies of NMN or NR covering CYP enzymes, transporters and pharmacodynamic interactions [20]. Interactions with a particular drug have not been established.

Is injectable NAD+ FDA approved?

No. Injectable or IV NAD+ is a compounded product rather than an FDA-approved drug [13]. No NAD+ product is approved to treat aging or any disease [6].

How long are the safety data for NMN and NR?

About 12 weeks. Human safety data beyond roughly 12 weeks are lacking, and the trials enrolled 12 to 140 people [20]. The highest daily doses tested were NMN 1,250 mg for up to 4 weeks and NR 3,000 mg/day for 4 weeks in Parkinson's disease [11][12].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Which NAD+ precursor is best?

No precursor has been shown to be better. The trials tested NMN and NR each against placebo, so they cannot show which raises NAD+ more, and neither has an established clinical benefit. Blood NAD+ rose with oral NMN in several randomized trials and with oral NR in a crossover trial.

What should you not mix with NAD?

No human drug-interaction studies of NMN or NR covering CYP enzymes, drug transporters or pharmacodynamic interactions were identified, so safety with any specific prescription drug has not been established. In the high-dose NR trial in Parkinson's disease, the apparent improvement tracked with a shorter interval since the last levodopa dose.

What evidence do you use when comparing NAD+ products?

The main evidence for NMN and NR comes from randomized trials that measured blood NAD+ before and after dosing. Nicotinic acid's evidence comes from its use as a lipid drug at gram doses, which is a different goal. Physical and metabolic outcomes for NMN and NR are mixed, and the trials were small and short.

References

Show all 22 references Hide references

1. Okabe K, Yaku K, Uchida Y, Fukamizu Y, Sato T, Sakurai T, et al. [Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects](https://pubmed.ncbi.nlm.nih.gov/35479740/). Front Nutr. 2022;9:868640.
2. Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, et al. [Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults](https://pubmed.ncbi.nlm.nih.gov/29599478/). Nat Commun. 2018;9(1):1286.
3. Prokopidis K, Moriarty F, Bahat G, McLean J, Church DD, Patel HP. [The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/40275690/). J Cachexia Sarcopenia Muscle. 2025;16(3):e13799.
4. Zhang J, Poon ET, Wong SH. [Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/39116016/). Crit Rev Food Sci Nutr. 2025;65(22):4382-4400.
5. Carlson LA. [Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review](https://pubmed.ncbi.nlm.nih.gov/16018787/). J Intern Med. 2005;258(2):94-114.
6. [Official web page](https://www.regulations.gov/document/FDA-2023-P-0872-2754).
7. Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, et al. [The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial](https://pubmed.ncbi.nlm.nih.gov/36482258/). Geroscience. 2023;45(1):29-43.
8. Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, et al. [Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures](https://pubmed.ncbi.nlm.nih.gov/31412242/). Cell Rep. 2019;28(7):1717-1728.e6.
9. Kim M, Seol J, Sato T, Fukamizu Y, Sakurai T, Okura T. [Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study](https://pubmed.ncbi.nlm.nih.gov/35215405/). Nutrients. 2022;14(4).
10. Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, et al. [Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women](https://pubmed.ncbi.nlm.nih.gov/33888596/). Science. 2021;372(6547):1224-1229.
11. Fukamizu Y, Uchida Y, Shigekawa A, Sato T, Kosaka H, Sakurai T. [Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women](https://pubmed.ncbi.nlm.nih.gov/36002548/). Sci Rep. 2022;12(1):14442.
12. Berven H, Kverneng S, Sheard E, Søgnen M, Af Geijerstam SA, Haugarvoll K, et al. [NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/38016950/). Nat Commun. 2023;14(1):7793.
13. [Bulk Drug Substances Used in Compounding of the FD&C Act | FDA](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act).
14. Avalos JL, Bever KM, Wolberger C. [Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme](https://pubmed.ncbi.nlm.nih.gov/15780941/). Mol Cell. 2005;17(6):855-68.
15. Igarashi M, Nakagawa-Nagahama Y, Miura M, Kashiwabara K, Yaku K, Sawada M, et al. [Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men](https://pubmed.ncbi.nlm.nih.gov/35927255/). NPJ Aging. 2022;8(1):5.
16. Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, et al. [A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects](https://pubmed.ncbi.nlm.nih.gov/29992272/). Am J Clin Nutr. 2018;108(2):343-353.
17. Brakedal B, Dölle C, Riemer F, Ma Y, Nido GS, Skeie GO, et al. [The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/35235774/). Cell Metab. 2022;34(3):396-407.e6.
18. [Official web page](https://www.regulations.gov/docket/FDA-2023-P-0872).
19. [Agency Response Letter GRAS Notice No. GRN 000635 | FDA](https://www.fda.gov/food/gras-notice-inventory/agency-response-letter-gras-notice-no-grn-000635).
20. Freeberg KA, Udovich CC, Martens CR, Seals DR, Craighead DH. [Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions](https://pubmed.ncbi.nlm.nih.gov/37068054/). J Gerontol A Biol Sci Med Sci. 2023;78(12):2435-2448.
21. Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, et al. [Nicotinamide riboside is uniquely and orally bioavailable in mice and humans](https://pubmed.ncbi.nlm.nih.gov/27721479/). Nat Commun. 2016;7:12948.
22. Reddit participants. [Which, Nicotinamide Riboside or Niacinamide (r/NicotinamideRiboside)](https://www.reddit.com/r/NicotinamideRiboside/comments/1ngq674/which_nicotinamide_riboside_or_niacinamide/). Accessed 2026-11-10.

Next in this cluster

Related reading

- [nad precursors NAD precursors](https://healthrx.com/classes-nad-precursors/class-overview-monograph)
- [nad precursors NAD precursors](https://healthrx.com/classes-nad-precursors/special-populations-summary)
- [nad precursors NAD precursors adverse events](https://healthrx.com/classes-nad-precursors/adverse-event-management)
- [nad precursors NAD precursors billing](https://healthrx.com/classes-nad-precursors/billing-and-prior-auth)
- [progestins vs synthetic Micronized progesterone](https://healthrx.com/classes-progestins/when-to-pick-which)
- [serms SERMs Billing & Prior-Auth Playbook](https://healthrx.com/classes-selective-er-modulators/billing-and-prior-auth)
- [testosterone formulations Testosterone formulations adverse events](https://healthrx.com/classes-testosterone-formulations/adverse-event-management)
- [testosterone formulations Testosterone billing](https://healthrx.com/classes-testosterone-formulations/billing-and-prior-auth)
- [testosterone formulations Testosterone formulations](https://healthrx.com/classes-testosterone-formulations/class-overview-monograph)
- [testosterone formulations Testosterone Formulations Drug-Drug Interaction Table](https://healthrx.com/classes-testosterone-formulations/ddi-table)
- [testosterone formulations Testosterone formulations monitoring bundle](https://healthrx.com/classes-testosterone-formulations/monitoring-bundle)
- [testosterone formulations Testosterone formulations](https://healthrx.com/classes-testosterone-formulations/titration-tapering-algorithm)

![NMN vs NR: man comparing two unlabeled supplement jars in a health store aisle](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/classes-nad-precursors/when-to-pick-which.webp)

Choosing between NMN and NR is difficult because no trial compared them directly and neither has an established clinical benefit. Full NAD precursors guide and sources at [healthrx.com/classes-nad-precursors](https://healthrx.com/classes-nad-precursors).

> Compounded drugs are not FDA-approved or reviewed by FDA for safety, effectiveness, or quality before marketing.
